Julie Collins
Hematology & Oncology · Washington, DCNPI 1134562069
Payments from drug & device makers
What this record shows
This record is dominated by education: $12 of the $12 with a category attached, or 100.0%. Every reported general payment came from a single manufacturer, Gilead. That places this record below the midpoint for hematology & oncology clinicians in DC, where the typical reported total is $4,025.
Across 1 payment — averaging $11.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$12
Across 22 payments — averaging $83,076 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$1.8M
What the payments were for
- Education$12100%
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 1 | $12 |
How this compares
$12 in reported general payments places this provider in the 0th percentile of 69 hematology & oncology providers in District of Columbia.
See all hematology & oncology providers in District of Columbia →
Other hematology & oncology in Washington
- Imadeddine TabbaraWashington$1.2M
- John MarshallWashington$525K
- Catherine BroomeWashington$504K
- Craig KesslerWashington$449K
- Benjamin WeinbergWashington$326K
- Claudine IsaacsWashington$241K
- Chul KimWashington$173K
- Christopher GallagherWashington$109K
- Neil ShahWashington$76K
- Vered StearnsWashington$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.